New drug aims to fortify the Body's defenses in rare immune disorder
NCT ID NCT05600920
Summary
This early-stage study is testing a new drug called NT-I7 (efineptakin alfa) to see if it is safe and can increase the number of a key type of immune cell (CD4 T cells) in people with idiopathic CD4 lymphopenia (ICL). ICL is a rare condition where people have very low levels of these cells, making them prone to serious infections. Up to 60 participants will receive three injections of the drug over 24 weeks, and researchers will closely monitor their health and immune cell counts for about a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC CD4 LYMPHOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.